Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myriad Genetics (MYGN) EPS (Basic) (2016 - 2026)

Myriad Genetics has reported EPS (Basic) over the past 17 years, most recently at -$0.07 for Q4 2025.

  • Quarterly EPS (Basic) rose 85.11% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.93 through Dec 2025, down 178.72% year-over-year, with the annual reading at -$3.95 for FY2025, 180.14% down from the prior year.
  • EPS (Basic) was -$0.07 for Q4 2025 at Myriad Genetics, up from -$0.29 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.31 in Q3 2021 and troughed at -$3.57 in Q2 2025.
  • The 5-year median for EPS (Basic) is -$0.32 (2023), against an average of -$0.51.
  • Year-over-year, EPS (Basic) skyrocketed 255.0% in 2021 and then crashed 770.73% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.1 in 2021, then crashed by 420.0% to -$0.52 in 2022, then soared by 34.62% to -$0.34 in 2023, then tumbled by 38.24% to -$0.47 in 2024, then soared by 85.11% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's EPS (Basic) are -$0.07 (Q4 2025), -$0.29 (Q3 2025), and -$3.57 (Q2 2025).